BioSante Pharmaceuticals Completes Both Pivotal LibiGel Efficacy Trials

BioSante Pharmaceuticals, Inc.

today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company's anticipated LibiGel new drug application. The final visit of the last subject enrolled in the second of the two pivotal LibiGel Phase III efficacy trials occurred at the end of September. LibiGel is in development for the treatment of female sexual dysfunction, specifically, hypoactive sexual desire disorder in menopausal women, for which there is no FDA-approved product.